News from biopharmadive.comFollowNews from biopharmadive.comSee all of biopharmadive.com news coverage in one place. Discover how biopharmadive.com’s media bias informs their coverage and compare with thousands of other news outlets.Overall, we’ve indexed 98 stories from biopharmadive.com over the past 3 months. The Ground News media bias check for biopharmadive.com is center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides. biopharmadive.com’s aggregated factuality score is high. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow See all of biopharmadive.com news coverage in one place. Discover how biopharmadive.com’s media bias informs their coverage and compare with thousands of other news outlets. Overall, we’ve indexed 98 stories from biopharmadive.com over the past 3 months. The Ground News media bias check for biopharmadive.com is center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides. biopharmadive.com’s aggregated factuality score is high. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about biopharmadive.comWhere is biopharmadive.com located?biopharmadive.com's WebsiteMedia Bias RatingsAverage Bias Rating:CenterCenterbyMedia Bias/Fact CheckDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: HighHighbyMedia Bias/Fact CheckLearn more about Factuality Ratings.Top biopharmadive.com NewsBusiness · United StatesFDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades50% Center coverage: 30 sourcesThe Food and Drug Administration on Thursday approved Bristol Myers Squibb’s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. See the StoryStock MarketsSickle Cell Disease Drug Pulled From Global Markets67% Center coverage: 3 sourcesPfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an imbalance in deaths among patients taking the drug. “The overall benefit of the drug no longer outweighs the risk in the approved sickle cell patient population,” the company announced on Wednesday, adding that the imbalance in […]See the StoryUnited States · United StatesFDA, after delay, clears Regeneron and Sanofi drug for COPD100% Center coverage: 2 sourcesDupixent is the first biologic medicine approved in the U.S. for the lung condition, though competitors from GSK, AstraZeneca and Roche could follow.See the StoryLatest News StoriesTopics Most Covered by biopharmadive.comStartupsPfizerMerckAstraZenecaVaccinesStartupsPfizerMerckSources Covering Similar TopicsEndpoints NewsSTATDataemiaMedCity NewsBizTocEndpoints NewsSTATDataemiaSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to biopharmadive.comMerckAstraZenecaStartupsPfizerNew York StateCalifornia, United StatesVaccinesUnited States